Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ING2 |
| Gene Name: | ING2 |
| Protein Full Name: | Inhibitor of growth protein 2 |
| Alias: | ING1L; ING1Lp; Inhibitor of growth 1-like; Inhibitor of growth 1-like protein; Inhibitor of growth family, member 1-like; Inhibitor of growth family, member 2; P32; P33ING2 |
| Mass (Da): | 32808 |
| Number AA: | 280 |
| UniProt ID: | Q9H160 |
| Locus ID: | 3622 |
| COSMIC ID: | ING2 |
| Gene location on chromosome: | 4q35.1 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 0.19 |
| Normal role description: | ING2 is part of the inhibitor of growth (ING) family.ING2 is implicated in p53/TP53 activation and p53/TP53-dependent apoptotic pathways. It seems to mosly function as a tumour suppressor protein, though upregulation is seen in colon cancer. |
| Commentary on involvement of protein in cancer: | Seems to be involved in p53/TP53 activation and p53/TP53-dependent apoptotic pathways, probably by enhancing acetylation of p53/TP53. Component of a mSin3A-like corepressor complex, which is probably involved in deacetylation of nucleosomal histones. ING2 activity seems to be modulated by binding to phosphoinositides (PtdInsPs). |